Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,440 across all filing types
Latest filing 2026-04-07 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
嘉事堂药业股份有限公司简式权益变动报告书（修订稿）
Major Shareholding Notification Classification · 95% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report" or "Equity Change Report". It details the change in shareholding of 嘉事堂药业股份有限公司 (Jia Shi Tang Pharmaceutical Co., Ltd.) by the information disclosure obligors 中国光大实业（集团）有限责任公司 and 中国光大医疗健康产业有限公司. The document extensively describes the transfer of shares via an agreement, the shareholding percentages before and after the transaction, the approval procedures required, and declarations by the parties involved. It is a detailed report on a change in major shareholding stakes, including the nature of the transaction (agreement transfer), the parties involved, and regulatory approvals pending. The document is over 13,000 characters, indicating it is a full report rather than a brief announcement. The content matches the definition of "Major Shareholding Notification (Code: MRQ)" which involves notification of changes in significant share ownership levels crossing thresholds. It is not an announcement of a report publication, nor a general regulatory filing, nor a proxy or voting result. Therefore, the correct classification is MRQ with high confidence.
2026-04-07 Chinese
中信证券股份有限公司关于嘉事堂药业股份有限公司详式权益变动报告书之财务顾问核查意见（修订版）
Capital/Financing Update Classification · 95% confidence The document is a detailed financial advisor's verification opinion on a "详式权益变动报告书" (Detailed Equity Change Report) related to a significant equity transaction involving 嘉事堂药业股份有限公司. It references compliance with Chinese securities laws and regulations, including the Securities Law, the Measures for the Administration of Takeovers of Listed Companies, and specific disclosure standards for equity change reports. The document includes extensive due diligence, verification of the equity change report contents, details on the transaction parties, shareholding changes, payment arrangements, and legal compliance. It is not a simple announcement but a comprehensive verification report by the financial advisor on the equity change report. This type of document fits the category of "Capital/Financing Update" (CAP), as it relates to a significant equity transaction and capital structure change, with detailed financial and legal review. It is not an Annual Report, Audit Report, or Management Report, nor is it a mere announcement or certification. Therefore, the correct classification is CAP with high confidence.
2026-04-07 Chinese
关于股东签署《交易价款支付确认协议》暨权益变动的进展公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding a shareholder transaction involving the transfer of a significant equity stake (28.48%) in the company 嘉事堂药业股份有限公司. It details the signing of a payment confirmation agreement related to the transaction price, the parties involved, payment arrangements, and regulatory approvals required. There is no financial statement or report data presented, but rather a disclosure of a change in major shareholding and related agreements. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2026-04-03 Chinese
关于向银行申请2026年综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's application for a comprehensive credit facility with a bank. It details the board meeting resolution to apply for a credit limit, the amount, and authorization for the chairman to sign related documents. There are no financial statements, earnings data, or detailed financial analysis. The document is a financing update about credit facilities, not a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification, so CAP is appropriate.
2026-03-13 Chinese
前期会计差错更正专项说明的鉴证报告
Regulatory Filings
2026-03-13 Chinese
2025年度独立董事述职报告(熊焰)
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 from 嘉事堂药业股份有限公司. It details the independent director's duties, attendance at board and committee meetings, review of related party transactions, internal controls, and protection of minority shareholders. The content is focused on governance and the independent director's oversight role rather than financial results or audit opinions. It is a formal report on the independent director's activities and governance compliance for the year, which fits the category of Board/Management Information (MANG) as it relates to board-level disclosures and management oversight rather than a full annual report, audit report, or other financial filings. The document length is 3475 characters, which is consistent with a detailed report but not a full annual report or earnings release. Therefore, the best classification is MANG with high confidence.
2026-03-13 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.